Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q2 2015 (← Previous) (Next →)

Filing Date: Aug 10, 2015

Total Value ($000): $198,055 (100.0% shares, 0.0% debt)

Holdings (7)

— Juno Therapeutics 37.0%

Value ($000) $73,329 Shares 1,375,000 Est. Cost $52.22 Unrealized —

— Paratek Pharmaceuticals 27.8%

Value ($000) $55,119 Shares 2,138,872 Est. Cost $38.55 Unrealized —

— Egalet 19.3%

Value ($000) $38,175 Shares 2,645,558 Est. Cost $5.69 Unrealized —

— FibroGen 11.5%

Value ($000) $22,846 Shares 972,175 Est. Cost $27.34 Unrealized —

— Proteon Therapeutics 2.3%

Value ($000) $4,465 Shares 250,000 Est. Cost $10.40 Unrealized —

— Dicerna Pharmaceuticals 1.6%

Value ($000) $3,117 Shares 223,457 Est. Cost $16.47 Unrealized —

— Achaogen 0.5%

Value ($000) $1,004 Shares 166,450 Est. Cost $13.05 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Juno Therapeutics	1,375,000	$73,329	37.0%	$52.22	—	Common Stock	48205A109
—	Paratek Pharmaceuticals	2,138,872	$55,119	27.8%	$38.55	—	Common Stock	699374302
—	Egalet	2,645,558	$38,175	19.3%	$5.69	—	Common Stock	28226B104
—	FibroGen	972,175	$22,846	11.5%	$27.34	—	Common Stock	31572Q808
—	Proteon Therapeutics	250,000	$4,465	2.3%	$10.40	—	Common Stock	74371L109
—	Dicerna Pharmaceuticals	223,457	$3,117	1.6%	$16.47	—	Common Stock	253031108
—	Achaogen	166,450	$1,004	0.5%	$13.05	—	Common Stock	004449104